APA (7th ed.) Citation

McMillan, M. T., Reyngold, M., Crane, C. H., O'Brien, D. A. R., Williams, V. M., Zinovoy, M., . . . Romesser, P. B. (2025). A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC). BMC Cancer, 25(1), 1. https://doi.org/10.1186/s12885-025-14779-5

Chicago Style (17th ed.) Citation

McMillan, Matthew T., et al. "A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response in Non-small Cell Lung Cancer (HAMMER-NSCLC)." BMC Cancer 25, no. 1 (2025): 1. https://doi.org/10.1186/s12885-025-14779-5.

MLA (9th ed.) Citation

McMillan, Matthew T., et al. "A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response in Non-small Cell Lung Cancer (HAMMER-NSCLC)." BMC Cancer, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1186/s12885-025-14779-5.